Evidence mapPaperPMID 32990683Full record

ArticleJCI insight2020

Acarbose has sex-dependent and -independent effects on age-related physical function, cardiac health, and lipid biology.

Jonathan J Herrera, Sean Louzon, Kaitlyn Pifer, Danielle Leander, Gennifer E Merrihew, Jea H Park, Kate Szczesniak, Jeremy Whitson, John E Wilkinson, Oliver Fiehn and 4 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Early or Late-Life Treatment With Acarbose or Rapamycin Improves Physical Performance and Affects Cardiac Structure in Aging Mice.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Geroprotectors and Skeletal Health: Beyond the Headlines.Frontiers in cell and developmental biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Jonathan J HerreraDepartment of Molecular & Integrative Physiology, University of Michigan (UM), Ann Arbor, Michigan, USA.
Sean LouzonDepartment of Molecular & Integrative Physiology, University of Michigan (UM), Ann Arbor, Michigan, USA.
Kaitlyn PiferDepartment of Pathology, UM Medical School, Ann Arbor, Michigan, USA.
Danielle LeanderDepartment of Pathology, UM Medical School, Ann Arbor, Michigan, USA.
Gennifer E MerrihewDepartment of Genome Sciences and.
Jea H ParkDepartment of Genome Sciences and.
Kate SzczesniakDepartment of Molecular & Integrative Physiology, University of Michigan (UM), Ann Arbor, Michigan, USA.
Jeremy WhitsonDepartment of Pathology, University of Washington, Seattle, Washington, USA.
John E WilkinsonUnit for Laboratory Animal Medicine and Department of Pathology, UM, Ann Arbor, Michigan, USA.
Oliver FiehnUCD, Genome Center, Davis, California, USA.
Michael J MacCossDepartment of Genome Sciences and.
Sharlene M DayDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Richard A MillerDepartment of Pathology, UM Medical School, Ann Arbor, Michigan, USA.
Michael GarrattDepartment of Pathology, UM Medical School, Ann Arbor, Michigan, USA.
Michigan Medicine · USUniversity of Michigan · USUniversity of California, Davis · USUniversity of Pennsylvania · USUniversity of Washington · US

Funding

Processing and Analyzing Mass Spectrometry Proteomics Data for the Longevity ConsortiumU19AG023122 · TRANSLATIONAL GENOMICS RESEARCH INST · 2004 to 2025
$16.8M
MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 1985 to 2005
$8.8M
PROGRAM ENRICHMENTP30AG013280 · UNIVERSITY OF WASHINGTON · 1995 to 2025
$6.6M
SPECIFICITY OF OXYGEN DNA DAMAGE AND MUTAGENESISP01AG001751 · UNIVERSITY OF WASHINGTON · 1985 to 2005
$6.2M
Research Education CoreP30AG024824 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2004 to 2025
$4.4M
GENETIC APPROACHES TO AGING RESEARCHT32AG000057 · UNIVERSITY OF WASHINGTON · 1985 to 2005
$3.8M
Laboratory for Anti-Geric Testing, Evaluation and Resea*U01AG022303 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2003 to 2025
$2.7M
SYTEMS AND INTEGRATIVE BIOLOGYT32GM008322 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 1990 to 2005
$1.7M
Structure, Composition, & Histology Core - Core BP30AR069620 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2025 to 2025
$693k
NIAMS NIH HHS P30 AR069620NIA NIH HHS P01 AG001751NIA NIH HHS P30 AG013280NIA NIH HHS P30 AG024824NIA NIH HHS T32 AG000057NIA NIH HHS U01 AG022303NIA NIH HHS U19 AG023122NIGMS NIH HHS T32 GM007863NIGMS NIH HHS T32 GM008322
6 · The paper itself

Abstract

With an expanding aging population burdened with comorbidities, there is considerable interest in treatments that optimize health in later life. Acarbose (ACA), a drug used clinically to treat type 2 diabetes mellitus (T2DM), can extend mouse life span with greater effect in males than in females. Using a genetically heterogeneous mouse model, we tested the ability of ACA to ameliorate functional, pathological, and biochemical changes that occur during aging, and we determined which of the effects of age and drug were sex dependent. In both sexes, ACA prevented age-dependent loss of body mass, in addition to improving balance/coordination on an accelerating rotarod, rotarod endurance, and grip strength test. Age-related cardiac hypertrophy was seen only in male mice, and this male-specific aging effect was attenuated by ACA. ACA-sensitive cardiac changes were associated with reduced activation of cardiac growth-promoting pathways and increased abundance of peroxisomal proteins involved in lipid metabolism. ACA further ameliorated age-associated changes in cardiac lipid species, particularly lysophospholipids - changes that have previously been associated with aging, cardiac dysfunction, and cardiovascular disease in humans. In the liver, ACA had pronounced effects on lipid handling in both sexes, reducing hepatic lipidosis during aging and shifting the liver lipidome in adulthood, particularly favoring reduced triglyceride (TAG) accumulation. Our results demonstrate that ACA, already in clinical use for T2DM, has broad-ranging antiaging effects in multiple tissues, and it may have the potential to increase physical function and alter lipid biology to preserve or improve health at older ages.

Indexed as

Physical Conditioning, AnimalAcarboseAge FactorsAgingAnimalsCardiomegalyFemaleGlycoside Hydrolase InhibitorsHeartLipidosesLiver DiseasesMaleMiceMice, Inbred BALB CMice, Inbred C3HMice, Inbred C57BLAcarboseGlycoside Hydrolase InhibitorsAgingCellular senescence

Identifiers

PMID32990683
PMCPMC7710286
OpenAlexW3090973681

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.